The jury of experts praised Olpha’s social projects such as the scholarship programme for young chemistry and biology teachers “Chemistry is among us!”, the provision of fist bumps for newborns in Olaine and other support initiatives aimed at improving the health and well-being of the Latvian population. The support provided by Olpha to the people of Ukraine was also significant. Since the outbreak of the war, Olpha has regularly cooperated with a number of Ukrainian aid organisations, donating both financial resources and useful items. The company’s cooperation with universities was also appreciated, as were its green energy projects and environmental protection activities.
“Olpha’s goal as a socially responsible company is to contribute to maximising the quality of people’s lives. While we do this primarily by enabling our patients to regain or improve their health with Olpha medicines, the company takes a much broader view of its contribution to the well-being of society by contributing financially, materially and in various other ways to and supporting socially relevant projects that aim to contribute to a better, happier and healthier community for all of us. We are very pleased that the company’s contribution and efforts have been recognised at such a high international level!” Juris Bundulis, Chairman of the Board of Olpha, is delighted.
In addition to various social projects, the company has been implementing environmentally friendly solutions, which has led to a 28.6% reduction in carbon emissions over the last five years. Olpha has also developed renewable energy sources that contribute to its energy efficiency targets. In autumn 2024, a solar panel park was inaugurated on the company’s premises, which will provide up to 40% of the company’s annual electricity consumption. Work is also underway on a new wastewater system.
It should be noted that Olpha will participate in the global pharmaceutical exhibition “CPHI Milan”, which will take place in Milan, Italy, from 8-10 October. The aim of the exhibition is to bring together pharmaceutical professionals, companies and organisations to promote collaboration, innovation, investment and development.
Participation in the international exhibition is part of the company’s activities aimed at introducing the Olpha brand and its medicines to the people of Western Europe, in order to achieve its goal of becoming one of the top ten European manufacturers of medicines in its therapeutic groups as soon as possible.